Biprotec

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Biprotec

Quick Facts

Property Description
Active Ingredient Flurbiprofen
Forms Tablets, capsules, ophthalmic solutions
Pharmacological Class Nonsteroidal Anti-inflammatory Drug (NSAID)
Origin Synthetic compound
General Purpose Analgesic, anti-inflammatory, and antipyretic relief

What Type of Medicine is Biprotec?

Biprotec is a specific medicinal preparation containing the single active substance Flurbiprofen, which is officially classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). This classification establishes its primary role in addressing pain and symptoms caused by inflammation. Flurbiprofen is recognized for its potent ability to reduce inflammation, distinguishing it as a key agent among propionic acid derivatives.

Flurbiprofen is a synthetic compound derived from phenylalkanoic acid, structurally belonging to the propionic acid class. It is designated as an anti-inflammatory and analgesic agent, particularly for conditions causing pain and inflammation. This confirms the medicine helps reduce swelling and ease the feeling of pain.

Composition, Forms, and General Purpose

The core composition of Biprotec features Flurbiprofen as the sole active agent, incorporated with appropriate excipients necessary for stability and delivery. This medication is available in various dosage forms, facilitating both systemic and local therapeutic effects.

These forms include oral dosage preparations, such as tablets and capsules, intended for ingestion to achieve a systemic effect, for example, relieving discomfort associated with conditions like chronic arthritis. Additionally, preparations like specialized ophthalmic solutions exist, allowing for local administration to a specific target site. Flurbiprofen is used in both systemic and localized applications. This indicates the drug can be used internally for general relief or externally for highly focused issues. The overall utility of this drug is to deliver reliable symptomatic relief, leveraging its inherent analgesic, anti-inflammatory, and antipyretic activities to manage discomfort associated with inflammatory processes.

What side effects are possible with Biprotec?

Official Side Effects and Safety Profile

Biprotec (Flurbiprofen) is classified by regulatory authorities as a Nonsteroidal Anti-inflammatory Drug (NSAID) and is subject to strict official warnings and contraindications.

Serious Adverse Reactions

Government regulatory agencies require labeling to highlight the potential for serious cardiovascular thrombotic events, including myocardial infarction (heart attack) and stroke, which can be fatal. This risk may increase with the duration of use. The medicine is also associated with an increased risk of serious gastrointestinal adverse events, such as bleeding, ulceration, and perforation of the stomach or intestines, which can occur without warning symptoms and may be fatal.

Other documented serious reactions include severe skin reactions (e.g., Stevens-Johnson syndrome, Toxic Epidermal Necrolysis), anaphylactic reactions, and hepatotoxicity (severe liver injury, including liver failure).

Frequency-Classified Adverse Reactions

The officially listed side effects are grouped by the body system affected and frequency:

Frequency System-Organ-Class (SOC) Examples Reactions
Common Gastrointestinal, Nervous System Headache, dizziness, dyspepsia, nausea, vomiting, abdominal pain, diarrhea, flatulence, constipation, fluid retention (edema)
Uncommon Immune System, Skin Hypersensitivity, visual impairment, asthma, dyspnoea, rash, pruritus, purpura, angioedema
Rare/Very Rare Renal, Blood, Psychiatric Anaphylactic reaction, depression, nephrotoxicity (e.g., renal failure), leukopenia, aplastic anaemia, hallucination, jaundice

Safety Restrictions and Considerations

  • Contraindications: Use is strictly prohibited in the setting of coronary artery bypass graft (CABG) surgery, in the third trimester of pregnancy (due to risk of harm to the fetus), and in patients with a history of allergic-type reactions (e.g., asthma, urticaria) after taking aspirin or other NSAIDs.
  • Population Notes: Elderly patients are noted to have a higher frequency of adverse reactions, particularly serious gastrointestinal events. Caution is required in patients with pre-existing renal, hepatic, or cardiac impairment due to the increased risk of acute kidney failure.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Flurbiprofen (Biprotec) overdose is defined by specific systemic manifestations and the explicit risk of severe, life-threatening outcomes. Due to these potential complications, regulatory documents state that emergency medical attention must be sought immediately upon any suspicion of overdose, and the Poison Help line should be contacted.

Documented overdose presentations commonly involve disturbances to the gastrointestinal and central nervous systems. Gastrointestinal symptoms can include nausea, vomiting, epigastric pain, and, in severe cases, gastrointestinal bleeding. Neurological signs include headache, agitation, drowsiness, tinnitus, and changes in consciousness, which may progress to semi-consciousness or loss of consciousness.

Severe outcomes officially documented include the potential for Convulsions (Seizures), Acute renal failure, CNS toxicity, and respiratory depression. Management is classified as strictly symptomatic and supportive, as no specific antidote is known. Procedures documented in regulatory texts may include the use of activated charcoal or gastric lavage within an appropriate timeframe, and the mandatory monitoring of cardiac and vital signs until stable.

Overdose risk and severity have specific population considerations. Regulatory information notes that elderly patients are at an increased risk of severe unwanted effects, and distinct symptoms, such as pinpoint pupils and elevated liver enzymes, have been reported in young children.

Therapeutic Uses of Biprotec

What Biprotec Treats: Main Uses and Benefits

Biprotec (Flurbiprofen) is generally used to provide essential symptomatic support across domains where symptoms related to physical discomfort interfere with daily functioning. Its utility is centered on addressing symptoms related to inflammatory or irritative states across acute, episodic, and chronic clinical settings. The medication is used in managing symptoms related to pain, tenderness, swelling, and stiffness.


Chronic Joint and Musculoskeletal Disorders

This domain covers the use of the medication in conditions characterized by periods of heightened symptoms, such as rheumatoid arthritis and osteoarthritis. Biprotec is applied in these clinical settings marked by increased discomfort to help ease the symptoms of joint pain, swelling, and persistent stiffness, which generally helps improve day-to-day comfort during symptomatic periods.

Acute and Episodic Inflammatory Pain

Biprotec is commonly used to help with symptom clusters associated with acute or episodic changes, such as tendinitis, soft-tissue trauma, and the discomfort of dysmenorrhea (menstrual cramps). It is relevant when symptoms become more noticeable, providing supportive relief when symptoms interfere with routine activities.


Quick Fact Therapeutic Relevance
Symptom Focus Easing Pain and Swelling
Chronic Use Support for Joint Stiffness in Arthritis
Episodic Use Management of Menstrual Discomfort

Regulatory References

  1. MedlinePlus Drug Information on Flurbiprofen

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

Biprotec (Flurbiprofen) is subject to specific regulatory eligibility criteria based on patient health status and age. The medicine is contraindicated (must not be used) in patients with a known history of allergic-type reactions to aspirin or other NSAIDs, or a history of active or recurrent gastrointestinal bleeding or peptic ulcers. Use is strictly prohibited in the setting of Coronary Artery Bypass Graft (CABG) surgery and for patients with severe hepatic, renal, or heart failure.

Use is also contraindicated during the last (third) trimester of pregnancy. Regarding age, the safety and efficacy of Biprotec are not established in children under 12 years of age, and its use is generally not recommended in this pediatric population. Elderly patients and those with mild to moderate impairment of liver or kidney function should use the medicine only with caution, typically at the lowest effective dosage for the shortest possible duration, as defined by official regulatory labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Biprotec (Flurbiprofen) establishes specific constraints when co-administered with other products, based on potential pharmacokinetic and pharmacodynamic effects.

Documented Interaction Patterns

Interaction Type Interacting Substances/Context Official Outcome Classification
Bleeding Risk Augmentation Anticoagulants (e.g., Warfarin), Antiplatelet Agents, SSRIs, SNRIs Synergistic effect on bleeding risk.
Antihypertensive Efficacy ACE Inhibitors, ARBs, Beta-Blockers May diminish the blood pressure-lowering effect.
Systemic Exposure Change Lithium, Aspirin (analgesic doses), Methotrexate, Pemetrexed Increases plasma concentration of Lithium; Aspirin lowers Flurbiprofen concentration.
Gastrointestinal Risk Alcohol, other NSAIDs, Tobacco Smoking Increased risk of gastric irritation and bleeding.

Regulatory Restrictions and Cautions

Use is contraindicated in the setting of Coronary Artery Bypass Graft (CABG) surgery and during the third trimester of pregnancy as defined in the official prescribing information. Co-administration with other NSAIDs or analgesic doses of aspirin is not generally recommended due to increased gastrointestinal toxicity risk. Caution is required when combining Biprotec with Diuretics or in specific populations, such as elderly or volume-depleted patients, where co-administration with ACE Inhibitors or ARBs may lead to deterioration of renal function. Administration with food or antacids may alter the rate but not the extent of the medicine's absorption.

Mechanism of Action

How Biprotec Works


Modulation of Cholesterol Production at the Source

Biprotec's primary mechanism involves the selective inhibition of ATP Citrate Lyase (ACL), a crucial enzyme found predominantly in the liver. ACL initiates the early, foundational step in the cholesterol synthesis pathway that generates new lipids within the cell. By acting as an inhibitor of this enzyme, the drug alters the rate of the liver's internal lipid production.


Enhanced Clearance via Circulating LDL Receptors

This molecular action of reducing internally synthesized cholesterol triggers a homeostatic signaling response in liver cells (hepatocytes). In consequence, the cells increase the expression and density of LDL receptors on their surface. These upregulated receptors actively bind to and sequester LDL cholesterol particles from the bloodstream, thereby enhancing the systematic clearance of LDL cholesterol from the circulation.

Dosage and Administration Information

Administration Guidelines: Official Use of Biprotec

Biprotec (Flurbiprofen) administration is defined for two distinct routes: systemic and local. The systemic oral route, primarily for tablets, specifies a total daily dosage range of 200 to 300 mg, which must be administered in divided doses two, three, or four times per day. The maximum single dose is 100 mg. For localized use, such as with the 8.75 mg oromucosal lozenge, the dose is taken every three to six hours as required, with a daily maximum of 5 doses.


Administration Conditions and Duration

Tablets must be swallowed whole and should be taken with food and a glass of water to ensure proper intake. The principle governing duration is to use the lowest effective dosage for the shortest duration consistent with treatment goals. For the localized oromucosal forms, use is generally restricted to a maximum of three days.


Population and Procedural Rules

Administration protocol includes specific guidance for certain patient groups. Safety and efficacy for the systemic oral route have not been established in children. Dose adjustment is required for individual patient needs, and caution is noted for use in older adults and patients with hepatic or renal impairment, where a reduced dose may be necessary. If a dose is missed, instructions advise against doubling the dose; instead, the patient should resume the regular schedule.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Biprotec


Evidence for use in Chronic Joint and Musculoskeletal Disorders

Research exploring Biprotec's systemic research profile for chronic musculoskeletal disorders primarily consists of Randomized Controlled Trials (RCTs). These studies were used in research exploring how symptoms change over time in conditions characterized by fluctuating manifestations, such as rheumatoid arthritis and osteoarthritis. Researchers monitored outcomes related to physical discomfort, including pain intensity, articular stiffness, and functional status scales in the observed populations.

Studies reported measurements of change in pain and stiffness scores against baseline in both the study drug and comparator/placebo groups. Subsequent meta-analyses consolidated and described these patterns of outcomes reported in the short-to-intermediate term. Long-term outcomes are not fully established by large-scale, controlled RCTs exceeding one year in duration for continuous study. The variability of individual patient response to the compound is a documented observation across the research base.


Evidence for use in Acute and Episodic Inflammatory Pain

Research has explored Biprotec in study populations with conditions associated with acute or disruptive episodes, such as primary dysmenorrhea (menstrual cramps) and acute pharyngitis (sore throat). The research primarily consists of short-term, placebo-controlled RCTs and systematic reviews.

These short-term trials reported specific measurements of symptom change over time, tracking metrics such as time to first change in sensation and overall pain scores over intervals of a few hours post-dose. The inherent short duration of acute-use trials limits the scope of data available for long-term outcomes associated with the repetitive use of the drug. Comparative evidence is also sometimes lacking for specific clinical scenarios within the acute pain context.


Evidence in Specific Patient Populations

Studies conducted for chronic conditions included patient cohorts that consisted of older adults (e.g., those aged 60 and over) alongside younger individuals to examine potential differences in reported outcomes. For localized formulations, trials were evaluated in adolescents (typically those 12 years and older) experiencing acute symptoms. However, most key clinical trials excluded individuals with severe or unstable pre-existing conditions. Consequently, data for certain groups—such as those with chronic underlying illnesses—remain insufficient, and results apply only to the specific populations studied in the RCTs.

Key Studies & References

  1. Strepsils Intensive 8.75 mg Lozenges - Summary of Product Characteristics (Regulatory Document detailing dosing and population safety)

Frequently Asked Questions (FAQ)

Common questions about Biprotec (FAQ)


Q: Is Biprotec considered a long-term treatment or is it short-term?

Official guidelines describe using the lowest effective dosage for the shortest duration possible consistent with a patient's treatment goals. Regulatory documents note that the risk of serious cardiovascular events, such as heart attack or stroke, may increase with a longer duration of use.


Q: Can Biprotec be used by older adults?

Regulatory documents state that older adults may use the medication, but caution is noted, as they are documented to have a higher frequency of adverse reactions, particularly serious gastrointestinal events. Official guidelines note that a reduced dose may be necessary for this population.


Q: Is Biprotec safe for teenagers to use?

Safety and effectiveness for the systemic (oral tablet) use of Biprotec are not established in the pediatric population (children). However, studies for localized formulations have been evaluated in adolescents (typically those 12 years and older).


Q: What kind of side effects are most commonly reported with Biprotec?

Officially listed common reactions include gastrointestinal issues such as nausea, diarrhea, and abdominal pain. Other common effects include nervous system issues like headache and dizziness.


Q: Does Biprotec affect the kidneys or liver?

The official label notes potential for serious liver injury (hepatotoxicity) and renal toxicity (kidney damage) as serious or rare adverse reactions associated with the medicine. Caution is noted for those with existing liver or kidney impairment.


Q: What happens if a person misses a dose of Biprotec?

Official instructions describe that if a dose is missed, it should not be doubled up to compensate; instead, use of the regular dosing schedule is noted.


Q: What do clinical trials suggest about Biprotec's effectiveness?

Clinical research, including Randomized Controlled Trials, has examined changes in symptoms such as pain intensity, stiffness, and functional status in chronic joint conditions, and the speed of symptom change in acute painful episodes.


Q: Does Biprotec need to be refrigerated or are there special storage instructions?

Official labeling states the medicine is stored at controlled room temperature, typically 20 C to 25 C (68°F to 77°F). It is to be protected from freezing, excess heat, light, and moisture in its original, tightly closed container.


Q: Can women who are planning to become pregnant use Biprotec?

Official regulatory documents require the drug to be avoided in the last (third) trimester of pregnancy due to potential risks to the fetus. There are no specific regulatory statements regarding its use during the pre-conception or early pregnancy planning stage.


Q: How quickly do people typically start noticing something after taking Biprotec?

For chronic conditions, such as those affecting the joints, official information suggests it may take up to one to two weeks to fully notice changes. For acute, localized pain, clinical trials have reported a rapid onset of symptom relief.


Q: Is there a generic version of Biprotec available?

Yes, the active ingredient Flurbiprofen is available in generic preparations listed in official regulatory and drug databases, such as DailyMed.


Q: Why is Biprotec sometimes mentioned with other drugs that seem similar?

Biprotec is officially classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). This is a class that includes other common medicines, and it is chemically related to other propionic acid derivatives.


Q: Can Biprotec be taken with common pain relievers like Tylenol (acetaminophen)?

No documented interaction is typically noted between Biprotec (Flurbiprofen) and acetaminophen (Tylenol) in official regulatory documents.


Q: Are there any specific foods or drinks to avoid while using Biprotec?

Official administration conditions note that the systemic medicine is generally taken with food. Use with alcohol and tobacco smoking is officially associated with an increased risk of gastrointestinal irritation and bleeding.


Q: Will taking Biprotec make me feel sleepy or tired?

Dizziness and headache are commonly listed side effects in official documents. Drowsiness has also been reported, and these effects are noted in the context of official warnings related to operating machinery.


Q: Is Biprotec a controlled substance?

No. Official drug databases classify Biprotec (Flurbiprofen) as a Nonsteroidal Anti-inflammatory Drug (NSAID) and do not list it as a federally controlled substance.


Q: Can Biprotec affect mood or cause emotional changes?

The official safety profile lists depression and hallucination as rare or very rare adverse reactions associated with the medication.


Q: Is there a possibility of becoming dependent on Biprotec?

Official assessments indicate that as an NSAID, Biprotec is not known to have a potential for abuse or dependence.


Q: Can I drive or operate machinery while taking Biprotec?

The official label states that if the medicine causes side effects like dizziness or blurred vision, official documentation indicates that activities such as driving or operating machinery should be avoided.


Q: Are there any restrictions on activity while using Biprotec?

The primary restriction noted in the official documentation is the recommendation to avoid driving or operating heavy machinery if a person experiences side effects like dizziness or blurred vision.


Q: Are there common reasons why Biprotec might not work for someone?

Clinical research has noted the variability of individual patient response to the compound. Official documentation does not list generalized common reasons for non-response, but individual results can vary widely across the population studied.


Q: Are there any known interactions between Biprotec and herbal supplements?

Official guidelines include a note that a healthcare provider should be informed about all medications and supplements, including herbal supplements, before starting Biprotec.

How should Biprotec be stored and disposed of?

How to Store and Dispose of Biprotec?

The official storage and disposal requirements for Biprotec (Flurbiprofen) are strictly defined by regulatory labeling to ensure product stability and safety.

Storage Requirements

Biprotec tablets must be stored at controlled room temperature, typically 20 C to 25 C, and protected from freezing, excess heat, light, and moisture. Keep the medicine in its original container and ensure the container is tightly closed to maintain product integrity. All forms of the medication must be stored in a location that is securely out of the sight and reach of children.

Disposal Instructions

Expired or unused Biprotec must be disposed of in accordance with local and national regulations for pharmaceutical waste. The official labeling advises against disposal through wastewater (sinks or toilets) or general sewer systems to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Biprotec found in:

A-Z Index: